Variable name;level;Overall;[0 -40);40+;p;test
;n;1351;799;550;;
Number of children;0;374 (27.7);271 (33.9);101 (18.4);<0.001;
;1;276 (20.4);175 (21.9);101 (18.4);;
;More than 1;701 (51.9);353 (44.2);348 (63.3);;
BMI;<18.5;78 (6.3);51 (6.9);27 (5.4);0.261;
;18.5-24.9;809 (64.9);493 (66.3);315 (62.9);;
;25-29.9;254 (20.4);141 (19.0);112 (22.4);;
;>=30;106 (8.5);59 (7.9);47 (9.4);;
BMI (mean);;22.6 [20.4, 25.4];22.3 [20.3, 25.1];22.9 [20.8, 26.0];0.003;nonnorm
Treatment center;Curie Paris;813 (60.2);483 (60.5);329 (59.8);0.860;
;Curie St Cloud;537 (39.8);316 (39.5);221 (40.2);;
Genetic analysis;No;651 (48.2);264 (33.0);386 (70.2);<0.001;
;Yes;700 (51.8);535 (67.0);164 (29.8);;
Hereditary predisposition;No;543 (79.3);409 (78.1);133 (83.1);0.203;
;Yes;142 (20.7);115 (21.9);27 (16.9);;
Inflammatory BC;No;1332 (98.7);786 (98.4);545 (99.1);0.375;
;Yes;18 (1.3);13 (1.6);5 (0.9);;
Clinical Tumor size (mm);;30.2 (21.5);32.4 (21.2);27.0 (21.6);<0.001;
Clinical T stage (TNM);T0-T1;588 (43.8);305 (38.5);282 (51.5);<0.001;
;T2;589 (43.9);381 (48.0);208 (38.0);;
;T3-T4;165 (12.3);107 (13.5);58 (10.6);;
Clinical N stage (TNM);N0;853 (63.6);494 (62.3);358 (65.3);0.282;
;N1-N2-N3;489 (36.4);299 (37.7);190 (34.7);;
SBR grade;Grade I;58 (4.3);27 (3.4);31 (5.7);<0.001;
;Grade II;524 (39.1);277 (35.0);247 (45.1);;
;Grade III;758 (56.6);487 (61.6);270 (49.3);;
BC subtype;Luminal;703 (57.6);383 (53.4);319 (63.5);0.003;
;TNBC;242 (19.8);163 (22.7);78 (15.5);;
;HER2+/HR+;195 (16.0);122 (17.0);73 (14.5);;
;HER2+/HR-;81 (6.6);49 (6.8);32 (6.4);;
Histological type;NST;1259 (93.3);760 (95.1);498 (90.7);0.001;
;Lobular;53 (3.9);18 (2.3);35 (6.4);;
;Others;37 (2.7);21 (2.6);16 (2.9);;
Neoajuvant chemotherapy;No;740 (54.8);379 (47.4);360 (65.5);<0.001;
;Yes;610 (45.2);420 (52.6);190 (34.5);;
Chemotherapy setting;Adjuvant;740 (54.9);379 (47.5);360 (65.5);<0.001;
;NAC;609 (45.1);419 (52.5);190 (34.5);;
Fertility preservation discussion;No;900 (66.7);388 (48.6);511 (92.9);<0.001;
;Yes;450 (33.3);411 (51.4);39 (7.1);;
